The US Food & Drug Administration should “consider more fluid and targeted guidance” to provide perspective advanced manufacturing technologies outside of individual product approvals, the National Academies of Science, Engineering & Medicine urges in a set of recommendations detailed in a new report.
The recommendation reflects concern that the Center for Drug Evaluation & Research’s “ability to foster innovation is fundamentally constrained by the center’s formal evaluation of technology only as it applies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?